Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
Sharma JD, Kataki AC, Barman D, Sharma A, Kalita M. Cancer statistics in Kamrup urban district: incidence and mortality in 2007–2011. Indian J Cancer. 2016;53:600–6.
Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979.
Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161.
Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited trans-hiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347:1662.
Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg. 2002;236:177.
Orringer MB, Marshall B, Iannettoni MD. Transhiatal esophagectomy: clinical experience and refinements. Ann Surg. 1999;230:392.
Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodal therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086–92.
van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.
Ando N, Kato H, Igaki Het al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.
Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695–704.
Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705–15.
Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.
Chan KKW, Saluja R, Delos Santos K, et al. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: a network meta-analysis. Int J Cancer. 2018;143:430.
Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: trial report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer. 2001;91(11):2165–74.
Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg S, et al. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma esophagus. J Thorac Cardiovasc Surg. 1988 Aug;96(2):242–8.
Hara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S, et al. Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci. 2013;104(11):1455–60. https://doi.org/10.1111/cas.12274 Epub 2013 Oct 18. PMID: 23991649.
Kapoor A, Kumar V, Singhal MK, Nirban RK, Beniwal SK, Kumar HS, et al. Socio-demographic parameters of esophageal cancer in Northwest India: a regional cancer center experience of 10 years. Indian J Community Med. 2015;40(4):264–7. https://doi.org/10.4103/0970-0218.164399.
Sehgal S, Kaul S, Gupta BB, Dhar MK. Risk factors and survival analysis of esophageal cancer in the population of Jammu, India. Indian J Cancer. 2012;49:245–50.
Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomized controlled trial. Lancet Oncol. 2015;16(9):1090 Epub 2015 Aug 5.
Mchembe MD, Rambau PF, Chalya PL, et al. Endoscopic and clinic-pathological patterns of esophageal cancer in Tanzania: experiences from two tertiary health institutions. World J Surg Oncol. 2013;11:257.
Boonstra JJ, Kok TC, Wijnhoven BP, van Heijl M, van Berge Henegouwen MI, Ten Kate FJ, et al. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer. 2011;11:181.
Cunningham D, Allum WH, Stenning SP, Thompson JN, Cornelis JH, de Velde V, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.
Klevebro F, von Döbeln GA, Wang N, Johnsen G, Jacobsen AB, Friesland S, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastro-oesophageal junction. Ann Oncol. 2016;27(4):660–7 Epub 2016 Jan 17.
Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet. 2002;359(9319):1727.
Bajwa HK, Singareddy R, Reddy MM, Raju KA, Rao ST, Rajappa SJ. Preoperative chemoradiation in carcinoma esophagus: experience from a tertiary cancer center in India. Indian J Med Paediatr Oncol. 2018;39:272–5.